Novonesis (Novozymes) B is the Class B share of Novonesis A/S, a leading biotechnology company headquartered in Lyngby, Denmark. Formed in 2024 through the merger of Novozymes and Chr. Hansen, it holds a dominant near-50% market share in industrial enzymes and microbial solutions worldwide. The company develops and supplies innovative biosolutions, including enzymes, functional proteins, and microorganisms, serving diverse industries such as household care, food and beverages, bioenergy, agriculture, animal feed, technical applications, and pharmaceuticals. These biological solutions enhance customer yield efficiency, performance, energy savings, and waste reduction, addressing global challenges in health, nutrition, and sustainability. With approximately 10,582 employees, over 30 research and development centers, and 23 manufacturing sites, Novonesis drives progress across essential sectors. Classified in the Basic Materials sector under Specialty Chemicals, it exemplifies large-growth characteristics with a strong patent portfolio and commitment to carbon neutrality by 2050.